Drug development has evolved through distinct eras, from small molecules to biologics, culminating in advanced cell and gene therapies.
2
Manufacturing challenges have become the primary hurdle in developing cell and gene therapies, shifting focus from drug discovery to production.
3
Cost remains a significant barrier in advanced therapies, particularly for rare diseases, necessitating strategies to reduce development and manufacturing expenses.
4
Funding for cell and gene therapy companies has become increasingly difficult to secure, mirroring trends seen during past economic downturns.
5
The consultancy emphasizes the importance of the 'five Ps'—People, Patent, Product, Profit, and PR—in assessing the viability of companies in the sector.
